# US 2018/0021420 A1 · Methods and compositions for inducing an immune response to egfrviii

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021420 A1
- Document ID: US20180021420A1
- Status: Published application
- Kind: A1
- Application number: 15/722,908
- Filed: 2017-10-02
- Published: 2018-01-25
- Earliest claimed: 2010-11-17
- Assignees: Aduro Biotech, Inc.; Providence Health & Services - Oregon d/b/a Providence Portland Medical Center
- Applicants: Aduro Biotech, Inc.; Providence Health & Services - Oregon D/B/A Provid Ence Portland Medical Center
- Inventors: Peter M. Lauer; Keith Bahjat
- Web page: https://patentgrep.com/patent/US20180021420A1

## CPC

- C07K 14/71: for growth factors; for growth regulators
- A61K 39/001104: {Epidermal growth factor receptors [EGFR]}
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/522: {avirulent or attenuated}
- A61K 2039/523: {expressing foreign proteins}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods of inducing a T-cell response against a EGFRvIII in a subject. These method comprise administering to a subject a composition which expresses at least one immunogenic polypeptide, the amino acid sequence of which comprise a plurality of EGFRvIII polypeptide sequences, the sequence of which each comprise EEKKGNYV (SEQ ID NO: 3), and/or administering the polypeptide itself.

## Claims

### Claim 1

A method of expressing an EGFRvIII polypeptide in a subject, said method comprising:
recombinantly expressing at least one polypeptide, the amino acid sequence of which comprise a plurality of EGFRvIII polypeptide sequences, the sequence of which each comprise EEKKGNYV (SEQ ID NO: 3), in said subject.

### Claim 2 (depends on 1)

The method of claim 1 wherein said plurality of EGFRvIII polypeptide sequences comprise one or more amino acid sequences selected from the group consisting of LEEKKGNYV (SEQ ID NO: 4), LEEKKGNYVVTDH (SEQ ID NO: 2), and PASRALEEKKGNYVVTDHGSC (SEQ ID NO: 5).

### Claim 3 (depends on 2)

The method of claim 2 wherein said plurality of EGFRvIII polypeptide sequences comprise at least three copies of PASRALEEKKGNYVVTDHGSC (SEQ ID NO: 5).

### Claim 4 (depends on 2)

The method of claim 2 wherein said plurality of EGFRvIII polypeptide sequences comprise at least five copies of PASRALEEKKGNYVVTDHGSC (SEQ ID NO: 5).

### Claim 5 (depends on 1)

The method of claim 1, wherein each EGFRvIII polypeptide sequence is flanked by a sequence which is configured to be cleaved by the proteasome.

### Claim 6 (depends on 5)

The method of claim 5, wherein each EGFRvIII polypeptide sequence is flanked by a sequence selected from the group consisting of ASKVL↓ADGSVK; ASKVA↓GDGSIK; LSKVL↓ADGSVK; LAKSL↓ADLAVK; ASVVA↓GIGSIA; GVEKI↓NAANKG; and DGSKKA↓GDGNKK (SEQ ID NOS: 6-12), wherein each arrow represents an EGFRvIII polypeptide sequence.

### Claim 7 (depends on 1)

The method of claim 1, wherein the polypeptide is expressed in said subject by administering a Listeria monocytogenes bacterium to the subject, wherein the Listeria monocytogenes bacterium comprises a nucleic acid sequence encoding said polypeptide integrated into the genome of said bacterium operably linked to control sequences which cause the expression of the polypeptide in the subject.

### Claim 8 (depends on 7)

The method of claim 7, wherein the bacterium is an actA deletion mutant or an actA insertion mutant, an inlB deletion mutant or an inlB insertion mutant or a ΔactA/ΔinlB mutant comprising both an actA deletion or an actA insertion and an inlB deletion or an inlB insertion.

### Claim 9 (depends on 8)

The method of claim 8, wherein said nucleic acid sequence is integrated into a virulence gene of said bacterium, wherein the integration of said nucleic acid sequence disrupts expression of the virulence gene or disrupts a coding sequence of the virulence gene.

### Claim 10 (depends on 9)

The method of claim 9, wherein the virulence gene is actA or inlB.

### Claim 11 (depends on 7)

The method of claim 7, wherein the bacterium is a Listeria monocytogenes prfA mutant, the genome of which encodes a prfA protein which is constitutively active.

### Claim 12 (depends on 7)

The method of claim 7, wherein the nucleic acid sequence is codon optimized for expression by Listeria monocytogenes.

### Claim 13 (depends on 7)

The method of claim 7, wherein said Listeria monocytogenes is administered to the subject by one or more routes of administration selected from the group consisting of orally, intramuscularly, intravenously, intradermally, and subcutaneously to said subject.

### Claim 14 (depends on 1)

The method of claim 1, wherein said polypeptide is expressed as a fusion protein comprising a secretory signal sequence.

### Claim 15 (depends on 14)

The method of claim 14, wherein the secretory signal sequence is a Listeria monocytogenes ActA signal sequence.

### Claim 16 (depends on 14)

The method of claim 14, wherein said polypeptide is expressed as a fusion protein comprising an in frame ActA-N100 sequence selected from the group consisting of SEQ ID NO:
28, SEQ ID NO: 29, SEQ ID NO: 30, and SEQ ID NO: 31, or an amino acid sequence having at least 90% sequence identity to said ActA-N100 sequence.

### Claim 17 (depends on 7)

The method of claim 7, wherein said polypeptide is expressed as a fusion protein comprising a secretory signal sequence.

### Claim 18 (depends on 7)

The method of claim 7, wherein the secretory signal sequence is a Listeria monocytogenes ActA signal sequence.

### Claim 19 (depends on 7)

The method of claim 7, wherein said method comprises administering a Listeria monocytogenes expressing the EGFRvIII polypeptide as a fusion protein comprising:
an ActA-N100 sequence selected from the group consisting of SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, and SEQ ID NO: 31 or an amino acid sequence having at least 90% sequence identity to said ActA-N100 sequence; and
a plurality of amino acid sequences having the sequence PASRALEEKKGNYVVTDHGSC (SEQ ID NO: 5), each of said plurality of amino acid sequences being flanked by a sequence which is configured to be cleaved by the proteasome,
wherein said fusion protein is expressed from a nucleic acid sequence operably linked to a Listeria monocytogenes ActA promoter.

### Claim 20 (depends on 1)

The method of claim 1, wherein said subject has an EGFRvIII-expressing tumor.

### Claim 21 (depends on 20)

The method of claim 20, wherein said subject has a glioma.

### Claim 22 (depends on 7)

The method of claim 7, wherein said bacterium, when administered to said subject, induces an increase in the serum concentration of one or more proteins selected from the group consisting of IL-12p70, IFN-γ, IL-6, TNF α, and MCP-1 at 24 hours following said administration.

### Claim 23 (depends on 7)

The method of claim 7, wherein said bacterium, when administered to said subject, induces an increase in the serum concentration of one or more proteins selected from the group consisting of IL-12p70, IFN-γ, IL-6, TNF α, and MCP-1 at 24 hours following said administration and induces a CD4+ and/or CD8+ antigen-specific T cell response against EGFRvIII.

### Claim 24

An isolated nucleic acid molecule encoding at least one immunogenic polypeptide, the amino acid sequence of which comprise a plurality of EGFRvIII polypeptide sequences, the sequence of which each comprise EEKKGNYV (SEQ ID NO: 3).

### Claim 25 (depends on 24)

The isolated nucleic acid molecule of claim 24 wherein said plurality of EGFRvIII polypeptide sequences comprise one or more amino acid sequences selected from the group consisting of LEEKKGNYV (SEQ ID NO: 4), LEEKKGNYVVTDH (SEQ ID NO: 2), and PASRALEEKKGNYVVTDHGSC (SEQ ID NO: 5).

### Claim 26 (depends on 24)

The isolated nucleic acid molecule of claim 24 wherein said plurality of EGFRvIII polypeptide sequences comprise at least three copies of PASRALEEKKGNYVVTDHGSC (SEQ ID NO: 5).

### Claim 27 (depends on 24)

The isolated nucleic acid molecule of claim 24 wherein said plurality of EGFRvIII polypeptide sequences comprise at least five copies of PASRALEEKKGNYVVTDHGSC (SEQ ID NO: 5).

### Claim 28 (depends on 24)

The isolated nucleic acid molecule of claim 24, wherein each EGFRvIII polypeptide sequence is flanked by a sequence which is configured to be cleaved by the proteasome.
